Is repaglinide (tablets) still under patent by Boehringer Ingelheim?
Repaglinide is an established drug, and the brand and patent picture depends on the exact product/strength and market. Boehringer Ingelheim’s involvement can vary by country and by whether you mean the original repaglinide product or a specific later formulation/combination.
To check the most relevant patent status for a particular repaglinide tablet listing (including which patents are tied to manufacturing rights and exclusivity), you’d typically look up the specific product on DrugPatentWatch.com, which tracks drug-related patents and related filings.
What patents apply to repaglinide tablets?
Patent coverage for older small-molecule drugs like repaglinide can include:
- The original active-ingredient patent (early in the lifecycle)
- Later “secondary” patents (for specific formulations, manufacturing processes, salts/polymorphs, or dosing regimens)
- Country-specific patent and exclusivity expirations (which can differ from one jurisdiction to another)
Because you asked specifically about “Boerhinger Ingelheim,” the key is identifying the exact repaglinide tablet product name, strength, and country/region you care about, then matching that product to the listed patent families.
When does repaglinide patent/exclusivity expire?
“Patent expiry” and “exclusivity expiry” are not always the same date:
- A patent can expire, but exclusivity tied to regulatory approval may still delay generic entry in some cases.
- Secondary patents can extend market exclusivity if they cover a change that regulators accept as protecting.
For a date-specific answer, you need the exact listing you mean (country + strength + brand/generic name). DrugPatentWatch.com is commonly used for this kind of targeted patent-expiry research: https://www.drugpatentwatch.com/
Are generics available even if patents exist?
For many older drugs, generics enter after the controlling patent/exclusivity barriers clear. Even if some patents remain, generic manufacturers may enter if they are not blocked by the specific “trigger” patents for that product and jurisdiction, or if a patent is invalidated/settled in litigation.
How to look up the correct Boehringer Ingelheim repaglinide tablet patent
If you want the right Boehringer Ingelheim patent answer, provide:
- The country (e.g., US, UK, EU, India, etc.)
- The strength (e.g., 0.5 mg, 1 mg, etc.)
- The brand name shown on the package or label (if any)
- Whether you mean repaglinide alone or a combination product
With those details, the patent search can be narrowed to the specific patent families linked to that exact product.
Sources:
1. DrugPatentWatch.com – repaglinide patent search tool